Amgen Inc. $AMGN Stock Acquired by Krilogy Financial LLC

Krilogy Financial LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 101.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,857 shares of the medical research company’s stock after acquiring an additional 5,981 shares during the quarter. Krilogy Financial LLC’s holdings in Amgen were worth $4,998,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. BlackRock Inc. lifted its position in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. State Street Corp grew its position in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after acquiring an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Amgen by 12.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after buying an additional 605,928 shares in the last quarter. Bank of America Corp DE acquired a new position in Amgen during the 2nd quarter valued at about $1,831,903,000. Finally, Invesco Ltd. lifted its position in Amgen by 7.2% in the fourth quarter. Invesco Ltd. now owns 4,788,460 shares of the medical research company’s stock worth $1,567,311,000 after purchasing an additional 321,173 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock worth $2,540,926 over the last quarter. 0.85% of the stock is owned by company insiders.

Amgen Stock Down 1.1%

AMGN stock opened at $412.84 on Wednesday. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock has a market capitalization of $223.19 billion, a price-to-earnings ratio of 18.67, a price-to-earnings-growth ratio of 3.01 and a beta of 0.41. The company has a 50-day moving average of $414.16 and a two-hundred day moving average of $373.24.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter last year, the firm posted $6.02 EPS. The company’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s payout ratio is presently 62.65%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Morgan Stanley cut their price objective on Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 7th. Guggenheim reduced their target price on Amgen from $388.00 to $378.00 and set a “neutral” rating for the company in a report on Tuesday. Argus raised their price objective on Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. BMO Capital Markets reduced their price target on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday. Finally, Sanford C. Bernstein increased their target price on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Amgen has an average rating of “Hold” and an average price target of $387.93.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.